Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Mulberry leaf extract tested for menopause symptom relief

NCT ID NCT07333885

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 10, 2026 · Updated 2 times

Summary

This study tests whether taking a daily mulberry leaf supplement (Reducose) with meals can improve blood sugar control and reduce perimenopause symptoms in women aged 40-60. Over 12 weeks, 120 participants will use a continuous glucose monitor and answer surveys about their symptoms and quality of life. The goal is to see if this natural supplement offers a simple way to ease common menopause-related issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

84 people

The number who actually took part.

Started

Dec 2025

Finished

Aug 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 60 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants assigned female at birth (aged 40-60 years) will be recruited for the study. * Females ages 40-60 who are weight stable and with a self- reported Body Mass Index (BMI) between 18.5 to 35 kg/m2. * Willing to maintain their existing dietary and physical activity patterns throughout the study period. * Have received a medical physical screening (annual physical) within the last 12 months where blood markers for diabetes were taken and results were within the healthy range. * Self-reported \>40yrs in age and experiencing irregular periods. * Willing and able to comply with the study protocol. * Has given voluntary informed consent to participate in the study. * Not currently using hormone replacement therapy (HRT) and/or \>3months since their last hormone treatment. * Experiencing menopause symptoms and meets the minimum score of 12/60 on the Greene Climacteric Scale (GCS). * Own or have constant access to a smart phone and the apple or android app stores and are willing and able to download the Dexcom and Chloe apps and accept their respective privacy policies. * Willing to practice a reliable method of non-hormonal contraception for the duration of the study. * In good general health at the time of screening (Investigator discretion). * Able to read, understand, and provide informed consent in English. * Able to receive shipment of the product at an address within the United States. * Able to complete study assessments over the course of up to 12 weeks. Exclusion Criteria: * Participants assigned male at birth. * Aged \> 60 or \< 40 years. * Pregnant or lactating. * Body mass index (BMI) \> 35kg/m2 or \< 18.5kg/m2 * Fasting blood glucose \>126mg/dL and/or HbA1c \>6.5% reported in routine medical physical screening within the last 12-months. * Known history of diabetes mellitus (Type I/II) or the use of antihyperglycemic drugs or insulin to treat diabetes and related conditions. * Currently using hormone replacement therapy (HRT) or had hormone therapy in the last 3 months. * Postmenopausal, experiencing amenorrhea for \>12months. * Underwent medically induced or surgical menopause. * History of hysterectomy or full or partial oophorectomy. * Any known food allergy or intolerance including mulberry extract. * Medical condition(s) or medication(s) known to affect glucose regulation or appetite and/or influence digestion and absorption of nutrients, including thyroid conditions, active inflammatory bowel disease (Crohn's disease or ulcerative colitis) and incretin mimetics (GLP-1, Semaglutide, Dulagluetide, Tirzepatide, etc.) * Previously undergone bariatric surgery. * Use steroids, protease inhibitors, antipsychotics, antidepressants (including selective serotonin reuptake inhibitors and monoamine oxidase inhibitors) (all of which have effects on glucose metabolism and body fat distribution). * Significant or untreated medical and/or psychiatric disorders including but not limited myocardial ischemia or infarction, unstable angina, uncontrolled hypertension, renal failure and serious renal diseases, undergoing dialysis, chronic active hepatitis, acute hepatitis, cirrhosis of liver, AIDS, malignancy or neurological disorders including epilepsy, recent cerebrovascular disease or recent traumatic brain injury. * Alcohol intake above recommendations (\>2 standard alcoholic drinks per day) or drug abuse or dependence within the past 6 months. * Currently smoke tobacco and cannabis products (including vaping). * Consuming extremely restrictive diet currently or within past 3 months. * Weight has varied significantly (+/- 5 lbs) in the past 3 months. * Cognitively impaired and/or who are unable to give informed consent. * Taking daily medications or dietary supplements that have a significant effect on blood glucose control either as a primary function or side effect. * Subject to a major medical, surgical or major depressive or psychiatric event requiring hospitalization within the preceding 3 months. * Use of over the counter medications like Herbal Supplements: Black Cohosh, Dong Quai, Maca Root, Red Clover, Chaste Tree Berry (Vitex), Soy Isoflavones, Ashwagandha; OTC Non-Herbal Supplements: DHEA, Progesterone Cream (Bioidentical), Melatonin. * Participation in any other clinical research trial within 30 days prior to randomization. * Do not have a personal smartphone, internet access, or unwilling to download Chloe or use a Dexcom Continuous Glucose Monitoring Device. * Are unlikely for any reason to be able to comply with the study protocol, do not provide informed consent, or considered unsuited for participation in the study by the Principal Investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glycemic response are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • People Science

    Los Angeles, California, 90034, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.